Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Genmab A/S's quarterly P/E stands at 167.4x, up 19117.5% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 4871.4% YoY to 25.2x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 17.57 | 167.39 | 11.80 | 1.51 | 15.79 | 0.87 | 3.13 | 2.90 | 3.70 | 8.21 | 2.73 | 4.61 | 29.50 |
| — | +19117.5% | +277.4% | -47.8% | +326.6% | -89.4% | +14.5% | -37.2% | -87.5% | -31.8% | +33.2% | +63.0% | +131.6% | |
| P/S Ratio | 4.48 | 4.91 | 4.66 | 0.55 | 4.38 | 0.52 | 0.71 | 5.23 | 8.14 | 1.12 | 1.23 | 1.50 | 2.19 |
| — | +844.8% | +552.4% | -89.6% | -46.2% | -53.6% | -42.1% | +248.7% | +271.3% | -17.9% | -4.9% | -11.5% | -22.1% | |
| P/B Ratio | 2.91 | 3.55 | 3.31 | 0.38 | 0.37 | 0.36 | 0.50 | 0.53 | 0.60 | 0.66 | 0.75 | 0.87 | 0.91 |
| — | +873.3% | +568.0% | -27.6% | -38.3% | -44.9% | -33.6% | -39.5% | -33.9% | -35.4% | -6.0% | -0.6% | -13.0% | |
| P/FCF | 14.50 | 18.02 | 8.91 | 9.72 | 1.79 | 11.18 | 1.99 | 18.96 | 22.84 | 3.26 | 3.00 | 18.46 | 1.98 |
| — | +61.2% | +347.4% | -48.8% | -92.2% | +242.6% | -33.5% | +2.7% | +1050.5% | -86.6% | +6.7% | +206.8% | -82.4% | |
| EV / EBITDA | 15.42 | 25.21 | 9.13 | 0.58 | 6.43 | 0.51 | 1.20 | 12.99 | 11.59 | 0.99 | 1.38 | 2.46 | 7.11 |
| — | +4871.4% | +663.2% | -95.5% | -44.5% | -48.8% | -13.2% | +428.9% | +62.9% | -44.4% | -3.9% | +5.0% | +7.7% | |
| EV / EBIT | 16.30 | 25.21 | 8.98 | 0.51 | 5.26 | 0.50 | 1.23 | 10.48 | 5.91 | 1.84 | 0.91 | 2.55 | 8.03 |
| — | +4913.4% | +627.3% | -95.2% | -10.9% | -72.6% | +35.6% | +311.4% | -26.5% | +2.7% | -38.5% | +3.7% | +30.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Genmab A/S's operating margin was 23.0% in Q4 2025, down 21.9 pp QoQ and down 10.6 pp YoY. The trailing four-quarter average of 33.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.7% | 92.3% | 94.3% | 93.8% | 94.1% | 94.8% | 95.1% | 96.4% | 95.5% | 97.3% | 98.3% | 99.5% | 100.0% |
| — | -2.6% | -0.8% | -2.7% | -1.5% | -2.6% | -3.3% | -3.1% | -4.5% | -2.7% | -1.7% | -0.5% | 0.0% | |
| Operating Margin | 33.6% | 23.0% | 44.9% | 38.9% | 26.3% | 33.5% | 37.9% | 30.3% | 19.2% | 35.7% | 35.8% | 35.2% | 14.7% |
| — | -31.5% | +18.4% | +28.5% | +36.7% | -6.1% | +6.1% | -14.0% | +30.7% | -28.8% | -24.3% | -10.7% | -39.3% | |
| Net Margin | 25.9% | 2.9% | 39.2% | 36.3% | 27.3% | 59.7% | 22.9% | 26.1% | 31.8% | 13.7% | 44.7% | 32.0% | 7.4% |
| — | -95.1% | +71.7% | +39.4% | -14.3% | +336.3% | -48.8% | -18.6% | +329.7% | +36.7% | -29.3% | -46.5% | -66.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 0.5% | 2.0% | 6.3% | 0.6% | 11.2% | 4.0% | 0.6% | 0.6% | 2.0% | 7.0% | 4.8% | 0.8% |
| — | -95.2% | -49.4% | +890.7% | -7.4% | +449.1% | -42.7% | -86.6% | -22.3% | +7.1% | -30.4% | -40.4% | -62.8% | |
| ROA | 3.3% | 0.3% | 1.7% | 5.2% | 0.4% | 9.0% | 3.2% | 0.5% | 0.5% | 1.8% | 6.3% | 4.3% | 0.7% |
| — | -96.5% | -48.3% | +864.0% | -15.8% | +395.7% | -48.3% | -87.4% | -23.1% | +7.3% | -29.5% | -40.7% | -63.0% | |
| ROIC | 5.0% | 2.7% | 2.3% | 6.5% | 0.5% | 6.0% | 5.8% | 0.8% | 0.5% | 7.1% | 7.0% | 6.4% | 1.9% |
| — | -55.4% | -61.1% | +753.7% | +8.7% | -16.5% | -16.5% | -88.1% | -74.2% | -35.6% | -22.6% | +0.4% | -33.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Genmab A/S's Debt/EBITDA ratio is 22.4x, up from 0.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 61.5% YoY to 2.02x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.93 | 0.93 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 |
| — | +3217.1% | -20.1% | -15.2% | -10.2% | +15.1% | +21.3% | +17.8% | +1.9% | +11.3% | +8.0% | +7.8% | +66.5% | |
| Debt / EBITDA | 4.10 | 22.40 | 0.30 | 0.39 | 4.60 | 0.46 | 0.45 | 4.08 | 7.83 | 0.45 | 0.45 | 0.53 | 1.76 |
| — | +4792.9% | -34.0% | -90.3% | -41.3% | +2.8% | +0.7% | +672.6% | +344.8% | +96.0% | +42.0% | +8.9% | +143.7% | |
| Current Ratio | 2.02 | 2.02 | 6.03 | 6.22 | 6.22 | 5.25 | 5.17 | 5.03 | 12.46 | 13.34 | 11.38 | 14.93 | 14.44 |
| — | -61.5% | +16.7% | +23.7% | -50.1% | -60.7% | -54.6% | -66.3% | -13.7% | -13.8% | +18.3% | +13.8% | -16.6% | |
| Quick Ratio | 2.01 | 2.01 | 6.01 | 6.20 | 6.20 | 5.24 | 5.15 | 5.02 | 12.42 | 13.32 | 11.36 | 14.90 | 14.44 |
| — | -61.6% | +16.7% | +23.5% | -50.1% | -60.7% | -54.6% | -66.3% | -14.0% | -14.0% | +18.1% | +13.6% | -16.6% | |
| Interest Coverage | 20.49 | 5.52 | 161.67 | 48.00 | 49.80 | 41.98 | 117.72 | 16.32 | 63.25 | 155.33 | 334.88 | 209.71 | 69.50 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying GMAB stock.
Genmab A/S's current P/E is 17.6x. The average P/E over the last 4 quarters is 49.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Genmab A/S's current operating margin is 33.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Genmab A/S's business trajectory between earnings reports.